Sarepta: Sarepta Therapeutics Details Strategic Roadmap for Third Quarter 2026 Financial Results and Recent Corporate Developments

Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs Strategic Priorities & Core Milestones Net product revenues for the third quarter 2026 totaled approximately $323.8 million, consisting of approximately $240.3 million of PMO net product revenues and $83.5 million of ELEVIDYS® net product revenue Detailing the operational roadmap, continued disciplined financial execution with positive cash flow and GAAP operating loss of ($9.0) million and non-GAAP operating income of $22.9 million for the third quarter 2026 Updates to 2026 guidance range include raising lower end of total net product revenue by $50.0 million, driven by strong PMO performance, and lowering higher end of expense by $25.0 million, reflecting operating discipline Program Benchmarks & Quantitative Progress Comprehensive program documentation and official disclosures outline key operational figures and quantitative benchmarks: Key Indicator: Established target milestone of $323.8 million under the active deployment framework. Key Indicator: Established target milestone of $240.3 million under the active deployment framework. Key Indicator: Established target milestone of $83.5 million under the active deployment framework. Key Indicator: Established target milestone of $9.0 under the active deployment framework. Key Indicator: Established target milestone of $22.9 million under the active deployment framework. Leadership Commentary & Official Insights Operational Alignment & Broader Impact Growing evidence base across ambulatory population reinforces ELEVIDYS benefit-risk profile, with new clinical, biomarker and real-world data supporting durability of benefit, robust dystrophin expression and approaches to liver safety risk mitigation In terms of implementation context, cAMBRIDGE, Mass.-(BUSINESS WIRE)-Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. "After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities," said Michael Severino, M.D., chief executive officer, Sarepta. "This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve. We are already preparing both programs for potential late-stage development with the intent of moving efficiently if the results support advancement. We have work to do, and I want us to be measured by execution, but I believe Sarepta has the commercial foundation, pipeline opportunities and financial strength to deliver meaningful long-term value." Strategic Outlook & Next Milestones Administrative bodies and departmental task forces will maintain active oversight across designated implementation cycles, ensuring scheduled deliverables translate into tangible public outcomes. Reporting and source materials courtesy of BusinessWire Global .